-
The Efficiency of Radiation Shielding Sheet to Reduce Radiation Exposure during C-arm Fluoroscopy
-
Hosang Jeon, Won Chul Shin, Hee Yun Seol, Yongkan Ki, Kyeong Baek Kim, Ki Seok Choo, Sang Don Lee, Suk-Woong Kang
-
J Korean Fract Soc 2023;36(4):111-117. Published online October 31, 2023
-
DOI: https://doi.org/10.12671/jkfs.2023.36.4.111
-
-
 Abstract
 PDF
- Purpose
This study evaluates the radiation shielding performance of a new lead-free tungsten-based sheet to reduce the radiation exposure of operators and patients under C-arm fluoroscopy.
Materials and Methods
A non-lead radiation shielding sheet (ROO201128; Pentas, Korea) was fabri-cated using tungsten and bismuth. The dose measurements were conducted using a C-arm fluoroscopy machine at 64 kVp and 1.5 mA, assuming two possible scenarios according to the position of the sheet. In each scenario, measurements were conducted at three distances (30, 60, and 90 cm) away from the beam center and in three directions (cephal, caudal, and operator’s direction).
Results
In the area within a radius of 60 cm from the beam center, the measured doses were reduced by 66.3% on mean, and the doses measured at distances more than 60 cm were less than 0.1 mSv/h in both scenarios. The most beneficial utilization of the lead-free shielding sheet was verified during C-arm fluoroscopy by placing the sheet on the X-ray tube. The operator’s radiation exposure was reduced by 56.6% when the sheet was placed under the phantom, and by 81.0% when the sheet was placed on the X-ray tube.
Conclusion
The use of lead-free radiation shielding sheets under C-arm fluoroscopy was effective in reducing radiation exposure, and the most beneficial scenario in which the sheet can be utilized was verified when the sheet was placed on the X-ray tube.
-
Romosozumab: A Novel Agent in the Management of Osteoporosis
-
Nam Hoon Moon, Won Chul Shin, Jae Hoon Jang
-
J Korean Fract Soc 2021;34(4):148-153. Published online October 31, 2021
-
DOI: https://doi.org/10.12671/jkfs.2021.34.4.148
-
-
Abstract
PDF
- With the discovery of screlostin as a pivotal player in bone metabolism, a novel medication targeting sclerostin has been introduced. Romosozumab, a humanized anti-sclerostin monoclonal antibody, is a unique approach to the treatment of osteoporosis that inhibits sclerostin, a key regulator that has the dual properties of promoting bone formation and inhibiting bone resorption. Romosozumab has been shown to be superior to conventional agents, in increasing bone mineral density and preventing osteoporotic fractures. Romosozumab may also be effective in the management of treatment-resistant osteoporosis and in the prevention of osteoporotic fractures in the very high risk population. However, further studies are necessary as there is insufficient data on its clinical efficacy and safety.
-
Citations
Citations to this article as recorded by  - The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II
Dong Ock Lee, Yeon Hee Hong, Moon Kyoung Cho, Young Sik Choi, Sungwook Chun, Youn-Jee Chung, Seung Hwa Hong, Kyu Ri Hwang, Jinju Kim, Hoon Kim, Dong-Yun Lee, Sa Ra Lee, Hyun-Tae Park, Seok Kyo Seo, Jung-Ho Shin, Jae Yen Song, Kyong Wook Yi, Haerin Paik, J
Journal of Menopausal Medicine.2024; 30(2): 55. CrossRef
-
75
View
-
2
Download
-
1
Crossref
|
E-submission
KFS
